iMetabolic Biopharma Corporation (iMBP) is an early stage platform biopharma company structured around development of First In Class therapeutics for treatment of various diseases having high unmet medical need. Through the application of its proprietary iPlatform technology, iMBP has established the firm as a Leader in TechBio, a new and emerging field of drug discovery and development driven by technology innovation. Having already established a pipeline of five early stage therapeutic assets, with additional molecules already in design phase, iMBP is at the precipice in its next leg of evolution. Based in Tempe, AZ; iMBP is growing its operations to support the development of both its platform technology and therapeutic pipeline. iMBP is now strategically poised to become a disruptive force in the biopharma industry and is poised to move forward ground breaking science to help improve patient care.
